Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting

BACKGROUND: Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited. METHOD: Efficacy and safety of PARPi/anti-PD-1 in advanced solid tumors were retrospectively ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhaozhen, Tao, Haitao, Zhang, Sujie, Wang, Xiao, Ma, Junxun, Li, Ruixin, Liu, Zhefeng, Wang, Jinliang, Cui, Pengfei, Chen, Shixue, Di, Huang, Huang, Ziwei, Zheng, Xuan, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423634/
https://www.ncbi.nlm.nih.gov/pubmed/33740125
http://dx.doi.org/10.1007/s00262-021-02852-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423634/
https://www.ncbi.nlm.nih.gov/pubmed/33740125
http://dx.doi.org/10.1007/s00262-021-02852-4

Ejemplares similares